← Azimuth Daily
Capturing data…
Capturing data…
MON, 5 OCT · 80 ITEMS
"High-dose vitamin B3 shows promise in glioblastoma trial, 82% progression-free at 6 months" — Science Daily (all) · Science & Medicine
A tested high-dose (vitamin B3) added to standard chemoradiation for , the most aggressive form of brain cancer. The study, published in the Journal of Neuro-Oncology in 2025 by University of Calgary researchers, reported that 82% of patients achieved survival at six months—an early but promising signal for a low-toxicity adjuvant therapy.
The claim derives directly from a peer-reviewed clinical trial paper in a reputable oncology journal, reported faithfully by Science Daily. As a Phase I–II trial with a single arm and modest sample size, the 82% progression-free rate is an encouraging early signal but should not be mistaken for definitive efficacy without a larger controlled study.
The underlying trial results date from 2025 (recirculation year given), so this represents a resurfacing of older material, not genuinely new findings.